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The Consortium for Blood Group Genes is a worldwide organization
whose goal is to have a vehicle to interact, establish guidelines,
operate a proficiency program, and provide education for labora-
tories involved in DNA and RNA testing for the prediction of blood
group, platelet, and neutrophil antigens. Immunohematology
2007;23:165–8.
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Background
The Consortium for Blood Group Genes (CBGG)
was started by a group of people interested in DNA
analyses for blood groups who recognized that there
was a growing need to establish guidelines and
proficiency testing. The originator and overall
coordinator is Marion Reid, and there are three country
coordinators: Lilian Castilho for Brazil, Gregory
Denomme for Canada, and Connie Westhoff for the
United States. All members are expected to interact and
participate. The background and progress, including the
CBGG logo, history, and mission, have been
published.1–3 The CBGG is a nonprofit organization
whose purpose is to provide a means for members to
interact, educate, and help each other. The purpose of
this report is to summarize the 2007 meetings, which
were held in two locations:North Carolina,USA,and São
Paulo, Brazil. It was written by the coordinator and
liaisons,with input from members (Table 1).
Discussion Documents
Two documents,one entitled the CBGG Document
and the other the CBGG Discussion Document,
containing items for discussion, were circulated to
members before the meeting and addressed by the
group at both meetings. The information given in the
CBGG Document was accepted with minor changes.
Suggestions from the group present at the meetings as
well as from those who sent comments via e-mail were
incorporated into the Document; this updated CBGG
Post Meeting Document 2007 was distributed to CBGG
members and is available to nonmembers on request.
Template disclaimers
It was decided that the disclaimer to accompany
reports of molecular analyses developed by the group
in 2006 was suitable for use in reporting donor and
patient test results. The disclaimer was modified to
reflect what DNA-based assays are intended for as well
as what they are not intended for. Reference to the
“FDA” and “CLIA” can be changed to include “Health
Canada,” “ANVISA” (Agencia Nacional de Vigilancia
Sanitaria) Brazil, or other regulating bodies as required.
Blood components should not be labeled with
molecular test results as the sole means of determining
the antigen status; the disclaimer statement must appear
on the product tag if that information is used. A separate
paper report with the disclaimer is adequate.
Guidelines for molecular testing
It was agreed that the CBGG should continue with
the development of “Standards” that are free and acces-
sible for general distribution. The CBGG “Standards”
have been shared with the AABB Molecular Testing
Standards Program Unit (SPU) and will be consistent
with the Standards being developed by them.A draft
version of the AABB Standards will be sent to all CBGG
members for review and comment. The CBGG
“Standards” will also be compared with the American
Society of Histocompatibility and Immunogenetics
(ASHI) Standards to be consistent with them. The CBGG
will discuss, modify, and finalize their “Standards” by
open discussion and present them in an International
Standards Organization (ISO) format and generic in
regards to regulatory agencies. The CBGG “Standards”
will be renamed“Guidelines” to reflect the fact that the
CBGG will not perform laboratory inspections.*a full listing of the members of the CBGG can be found inTable 1 on page 166.
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Reimbursement codes
A list of Current Procedural Terminology codes for
reimbursement in U.S. facilities has been included in the
CBGG Post Meeting Document.
Conclusion
The CBGG is a self-help, nonprofit organization
designed for members to support and to learn from
each other. Anyone interested in molecular testing for
blood groups and willing to contribute intellectually
is welcome to join. To become a member, contact
Marion Reid (mreid@nybloodcenter.org),Lilian Castilho
(castilho@unicamp.br),Greg Denomme (greg.denomme
@bloodservices.ca), or Connie Westhoff (WesthoffC@
usa. redcross.org).
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Target alleles
A list of target single-nucleotide polymorphisms
(SNPs) was prepared for the CBGG Post Meeting
Document 2007. Blood groups requiring analysis of
more than one SNP to minimize the chance of
misinterpretation were noted and are required. Control
DNA samples were recommended.
Reorganization of proficiency program
A simple exchange of samples among several
laboratories performing DNA assays for the prediction of
blood group antigens has been in effect and operated
by Marion Reid and Kim Hue-Roye since the CBGG was
formed in 2004. Samples are exchanged in the spring
and fall. DNA (or whole blood) from one sample is sent
for testing for a defined SNP. For RBC typing, before
shipping the proficiency sample, the predicted antigen
was confirmed by a method other than DNA testing (i.e.,
hemagglutination) with the caveat that the proficiency
exercise would not involve rare alleles and should be
straightforward. Along the same lines, the proficiency
testing program for platelet and neutrophil antigens
(which is in development) should also be
straightforward and not involve rare alleles. But unlike
RBC typing, confirmation of the antigen(s) would be
based on the DNA results only. Methods such as
monoclonal antibody immobilization of platelet antigens
(MAIPA) or modified antigen capture ELISA (MACE)
assays are not usually performed for typing confirmation.
Results obtained by the testing laboratories are returned
to the submitting laboratory, which then confirms (or
not) the results and interpretation. A form has been
developed for this purpose, a copy of which is
contained in the CBGG Post Meeting Document 2007.
It was decided, starting October 2007, that the
“submitting laboratory” should rotate among members
of the Proficiency Program. For logistic reasons, there
will be two programs;one with an exchange among the
SouthAmerican members and the other among all other
interested members. It was also agreed that one
proficiency sample would be used for all types of
technology: microarray, PCR-RFLP, multiplex, and so
forth. If more than one laboratory is in disagreement
with the submitting laboratory, there will be an
investigation. If only one laboratory is different, that
laboratory should perform its own internal investi-
gation. The NewYork Blood Center remains the overall
coordinator.
